Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2008 1
2009 1
2010 2
2011 6
2012 5
2013 6
2014 4
2015 7
2016 14
2017 11
2018 16
2019 12
2020 15
2021 12
2022 9
2023 5
2024 1

Text availability

Article attribute

Article type

Publication date

Similar articles for PMID: 36456153

102 results

Results by year

Filters applied: . Clear all
Page 1
Dose-dependent efficacy of bevacizumab in recurrent glioblastoma.
Melhem JM, Tahir A, Calabrese E, Granovskaya I, Atenafu EG, Sahgal A, Lim-Fat MJ, Perry JR. Melhem JM, et al. J Neurooncol. 2023 Feb;161(3):633-641. doi: 10.1007/s11060-023-04248-z. Epub 2023 Feb 7. J Neurooncol. 2023. PMID: 36749445
A comprehensive analysis of factors related to carmustine/bevacizumab response in recurrent glioblastoma.
Cardona AF, Rojas L, Wills B, Ruiz-Patiño A, Abril L, Hakim F, Jiménez E, Useche N, Bermúdez S, Mejía JA, Ramón JF, Carranza H, Vargas C, Otero J, Archila P, Rodríguez J, Rodríguez J, Behaine J, González D, Jacobo J, Cifuentes H, Feo O, Penagos P, Pineda D, Ricaurte L, Pino LE, Vargas C, Marquez JC, Mantilla MI, Ortiz LD, Balaña C, Rosell R, Zatarain-Barrón ZL, Arrieta O. Cardona AF, et al. Clin Transl Oncol. 2019 Oct;21(10):1364-1373. doi: 10.1007/s12094-019-02066-2. Epub 2019 Feb 23. Clin Transl Oncol. 2019. PMID: 30798512
Prognostic factors in recurrent glioblastoma patients treated with bevacizumab.
Schaub C, Tichy J, Schäfer N, Franz K, Mack F, Mittelbronn M, Kebir S, Thiepold AL, Waha A, Filmann N, Banat M, Fimmers R, Steinbach JP, Herrlinger U, Rieger J, Glas M, Bähr O. Schaub C, et al. J Neurooncol. 2016 Aug;129(1):93-100. doi: 10.1007/s11060-016-2144-7. Epub 2016 May 18. J Neurooncol. 2016. PMID: 27193554
Randomized phase II trial of irinotecan and bevacizumab as neo-adjuvant and adjuvant to temozolomide-based chemoradiation compared with temozolomide-chemoradiation for unresectable glioblastoma: final results of the TEMAVIR study from ANOCEF†.
Chauffert B, Feuvret L, Bonnetain F, Taillandier L, Frappaz D, Taillia H, Schott R, Honnorat J, Fabbro M, Tennevet I, Ghiringhelli F, Guillamo JS, Durando X, Castera D, Frenay M, Campello C, Dalban C, Skrzypski J, Chinot O. Chauffert B, et al. Ann Oncol. 2014 Jul;25(7):1442-1447. doi: 10.1093/annonc/mdu148. Epub 2014 Apr 9. Ann Oncol. 2014. PMID: 24723487 Free article. Clinical Trial.
Bevacizumab Plus Irinotecan Versus Temozolomide in Newly Diagnosed O6-Methylguanine-DNA Methyltransferase Nonmethylated Glioblastoma: The Randomized GLARIUS Trial.
Herrlinger U, Schäfer N, Steinbach JP, Weyerbrock A, Hau P, Goldbrunner R, Friedrich F, Rohde V, Ringel F, Schlegel U, Sabel M, Ronellenfitsch MW, Uhl M, Maciaczyk J, Grau S, Schnell O, Hänel M, Krex D, Vajkoczy P, Gerlach R, Kortmann RD, Mehdorn M, Tüttenberg J, Mayer-Steinacker R, Fietkau R, Brehmer S, Mack F, Stuplich M, Kebir S, Kohnen R, Dunkl E, Leutgeb B, Proescholdt M, Pietsch T, Urbach H, Belka C, Stummer W, Glas M. Herrlinger U, et al. J Clin Oncol. 2016 May 10;34(14):1611-9. doi: 10.1200/JCO.2015.63.4691. Epub 2016 Mar 14. J Clin Oncol. 2016. PMID: 26976423 Clinical Trial.
Neoadjuvant bevacizumab and irinotecan versus bevacizumab and temozolomide followed by concomitant chemoradiotherapy in newly diagnosed glioblastoma multiforme: A randomized phase II study.
Hofland KF, Hansen S, Sorensen M, Engelholm S, Schultz HP, Muhic A, Grunnet K, Ask A, Costa JC, Kristiansen C, Thomsen C, Poulsen HS, Lassen U. Hofland KF, et al. Acta Oncol. 2014 Jul;53(7):939-44. doi: 10.3109/0284186X.2013.879607. Epub 2014 Jan 23. Acta Oncol. 2014. PMID: 24456504 Clinical Trial.
Quality of life in the GLARIUS trial randomizing bevacizumab/irinotecan versus temozolomide in newly diagnosed, MGMT-nonmethylated glioblastoma.
Schäfer N, Proescholdt M, Steinbach JP, Weyerbrock A, Hau P, Grauer O, Goldbrunner R, Friedrich F, Rohde V, Ringel F, Schlegel U, Sabel M, Ronellenfitsch MW, Uhl M, Grau S, Hänel M, Schnell O, Krex D, Vajkoczy P, Tabatabai G, Mack F, Schaub C, Tzaridis T, Nießen M, Kebir S, Leutgeb B, Urbach H, Belka C, Stummer W, Glas M, Herrlinger U. Schäfer N, et al. Neuro Oncol. 2018 Jun 18;20(7):975-985. doi: 10.1093/neuonc/nox204. Neuro Oncol. 2018. PMID: 29121274 Free PMC article. Clinical Trial.
102 results